Breast

Organic Remedies Will Be Lighting the Sky Pink During Its Annual Breast Cancer Awareness Campaign

Retrieved on: 
Monday, September 26, 2022

PBCC is a local nonprofit that supports and serves breast cancer survivors and their families in Pennsylvania through educational programming, legislative advocacy, and breast cancer research grants.

Key Points: 
  • PBCC is a local nonprofit that supports and serves breast cancer survivors and their families in Pennsylvania through educational programming, legislative advocacy, and breast cancer research grants.
  • In recognition of the work that still needs to be done to eradicate breast cancer, Organic Remedies is removing the covers from the LED lights at its medical marijuana greenhouse in Carlisle, PA, to light the sky pink.
  • Patients can also pick up informational materials about breast cancer and support services for those with breast cancer and their families in all Organic Remedies dispensary locations.
  • We are delighted to work with Organic Remedies again this year to raise funds to help breast cancer survivors and their families.

Tommy Bahama Launches Breast Cancer Awareness Month Capsule Collection to Celebrate Its Support of the Breast Cancer Research Foundation (BCRF)

Retrieved on: 
Monday, September 26, 2022

SEATTLE, Sept. 26, 2022 /PRNewswire/ -- In honor of Breast Cancer Awareness month this October, Tommy Bahama will debut a special capsule collection of women's sportswear and select men's pieces to celebrate its support of The Breast Cancer Research Foundation (BCRF).

Key Points: 
  • SEATTLE, Sept. 26, 2022 /PRNewswire/ -- In honor of Breast Cancer Awareness month this October, Tommy Bahama will debut a special capsule collection of women's sportswear and select men's pieces to celebrate its support of The Breast Cancer Research Foundation (BCRF).
  • The BCRF is anon-profit organization whose mission is to prevent and cure breast cancer by advancing the world's most promising research.
  • The Tommy Bahama Breast Cancer Awareness capsule collection will be available in October in stores and online at tommybahama.com .
  • Tommy Bahama will donate 100% of contributions to the Breast Cancer Research Foundation (BCRF).

PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 23, 2022

Each stock option has an exercise price of$3.18,the closing price of PDS Biotechs common stock on September 22, 2022.

Key Points: 
  • Each stock option has an exercise price of$3.18,the closing price of PDS Biotechs common stock on September 22, 2022.
  • PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on the Companys proprietary Versamune and Infectimune T-cell activating technology platforms.
  • PDS Biotech has developed multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them.
  • Versamune is a registered trademark and Infectimune is a trademark of PDS Biotechnology.

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Ann Taylor and LOFT Expand BCRF Partnership with New Campaign Better Together: A Sisterhood of Strength

Retrieved on: 
Thursday, September 22, 2022

Through powerful stories told directly by women impacted by and living with breast cancer, Ann Taylor and LOFT have created A Sisterhood of Strength that celebrates unstoppable women who only get stronger.

Key Points: 
  • Through powerful stories told directly by women impacted by and living with breast cancer, Ann Taylor and LOFT have created A Sisterhood of Strength that celebrates unstoppable women who only get stronger.
  • Ann Taylor and LOFT are committed to supporting women, and every woman has been affected by breast cancer in some way.
  • Ann Taylor and LOFT have stood by our side year after year, said BCRF President and Chief Executive Officer, Myra Biblowit.
  • For more information about Ann Taylor and LOFT and their partnership with BCRF, visit www.anntaylor.com/anntaylorcares and www.loft.com/loftcares .

FDA Grants QT Imaging™ Clearance to Calculate Fibroglandular Volume of the Breast

Retrieved on: 
Thursday, September 22, 2022

NOVATO, Calif., Sept. 22, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV). This ratio can contribute to an assessment of risk for breast cancer and changes in this ratio can be used to measure the efficacy of medication used to treat or prevent breast cancer.

Key Points: 
  • NOVATO, Calif., Sept. 22, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV).
  • No other ultrasound-based breast imaging modality is cleared by the FDA to quantify fibroglandular volume.
  • The company has received FDA 510(K) clearance for its QT Imaging Breast Scanner.
  • The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast.

Annabelle Gurwitch to Emcee Lung Cancer Research Foundation Gala

Retrieved on: 
Wednesday, September 21, 2022

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Ms. Annabelle Gurwitch, who was diagnosed with Stage IV EGFR non-small cell lung cancer when she went in for a COVID-19 test in 2020, will emcee the Lung Cancer Research Foundation's (LCRF) 2022 Evening of Innovation Gala, honoring Dr. Brendon M. Stiles. Ms. Gurwitch recently shared remarks at the opening plenary session of International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Vienna, Austria.

Key Points: 
  • Actor, activist, and author teams up with the Lung Cancer Research Foundation to increase awareness of lung cancer and honor Dr. Brendon M. Stiles for his service to the foundation and the lung cancer community
    NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Ms. Annabelle Gurwitch, who was diagnosed with Stage IV EGFR non-small cell lung cancer when she went in for a COVID-19 test in 2020, will emcee the Lung Cancer Research Foundation's (LCRF) 2022 Evening of Innovation Gala, honoring Dr. Brendon M. Stiles.
  • "Dr. Stiles' personal and professional contribution to lung cancer patients and his commitment to accelerating lung cancer research is immeasurable.
  • The Lung Cancer Research Foundation (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer.
  • LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.

Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody

Retrieved on: 
Wednesday, September 21, 2022

Through this global partnership, Abpro will receive payments from Celltrion of up to $1.75 Billion, including an equity investment, development and commercial milestone payments and worldwide profit sharing.

Key Points: 
  • Through this global partnership, Abpro will receive payments from Celltrion of up to $1.75 Billion, including an equity investment, development and commercial milestone payments and worldwide profit sharing.
  • Celltrion will be in charge of the development of ABP 102 following the completion of in vitro studies by Abpro and will have world-wide commercialization rights.
  • HER2+ type cancer is implicated in up to 30% of all cases in breast, gastric, pancreatic, and other forms of cancer.
  • We are confident this partnership will allow us to deliver the best possible care to patients suffering from HER2+ cancer.

Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022

Retrieved on: 
Wednesday, September 21, 2022

Veru is a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers.

Key Points: 
  • Veru is a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers.
  • The Company has completed a positive Phase 3 COVID-19 study evaluating sabizabulin in hospitalized moderate to severe COVID-19 patients at high risk for ARDS.
  • A double-blind, randomized, placebo-controlled Phase 3 COVID-19 clinical trial was conducted in 204 hospitalized COVID-19 patients with moderate to severe COVID at high risk for ARDS and death.
  • Verus late-stage prostate cancer portfolio comprises sabizabulin, VERU-100, a long-acting GnRH antagonist, and zuclomiphene citrate, an oral nonsteroidal estrogen receptor agonist.

Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor

Retrieved on: 
Wednesday, September 21, 2022

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l.

Key Points: 
  • Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l.
  • (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293.
  • Under the current agreement, Merck KGaA, Darmstadt, Germany will make early payments (up-front and option exercise fees) of up to $65 million to NMS.
  • Upon exercise of the option, NMS will grant to Merck KGaA, Darmstadt, Germany the exclusive rights to research, develop, manufacture, and commercialize NMS-293.